NEW YORK (Reuters Health) -- An updated review of medications available for treating type 2 diabetes concludes that metformin continues to have the best benefit-to-harm profile, according to a report in the Annals of Internal Medicine online March 14.
For more information, please visit: http://www.thedoctorschannel.com/video/4166.html
Link to this comment:
All Comments (0)